207 related articles for article (PubMed ID: 8590842)
1. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
Mahon FX; Belloc F; Vianes I; Barbot C; Boiron JM; Cowen D; Lacombe F; Brizard A; Bilhou-Nabera C; Bernard P
Leuk Lymphoma; 1995 Nov; 19(5-6):423-9. PubMed ID: 8590842
[TBL] [Abstract][Full Text] [Related]
2. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
3. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
Skórski T; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations.
Chasty R; Whetton A; Lucas G
Leuk Res; 1996 May; 20(5):391-5. PubMed ID: 8683978
[TBL] [Abstract][Full Text] [Related]
6. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
[TBL] [Abstract][Full Text] [Related]
7. Effect of antisense oligonucleotides on CD34+ cells from chronic myeloid leukemia.
Pigneux A; Mahon FX; Jazwiec B; Pigeonnier V; Ripoche J; Reiffers J
Leuk Lymphoma; 2000 Feb; 36(5-6):569-78. PubMed ID: 10784402
[TBL] [Abstract][Full Text] [Related]
8. Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides.
Lanza F; Bi S; Moretti S; Castoldi G; Goldman JM
Br J Haematol; 1995 May; 90(1):8-14. PubMed ID: 7786800
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of hematopoietic colonies derived from chronic myeloid leukemia patients: interphase fluorescence in situ hybridization compared with RT-PCR.
Thijsen SF; Schuurhuis GJ; van Oostveen JW; Theijsmeijer AP; Langenhuijsen MM; Ossenkoppele GJ
Leukemia; 1997 Feb; 11(2):301-5. PubMed ID: 9009097
[TBL] [Abstract][Full Text] [Related]
10. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
[TBL] [Abstract][Full Text] [Related]
11. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Zon G; Iozzo RV; Calabretta B
Blood; 1996 Aug; 88(3):1005-12. PubMed ID: 8704208
[TBL] [Abstract][Full Text] [Related]
13. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides.
Ratajczak MZ; Hijiya N; Catani L; DeRiel K; Luger SM; McGlave P; Gewirtz AM
Blood; 1992 Apr; 79(8):1956-61. PubMed ID: 1562723
[TBL] [Abstract][Full Text] [Related]
14. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
Gewirtz AM
Leuk Lymphoma; 1993; 11 Suppl 1():131-7. PubMed ID: 7504543
[TBL] [Abstract][Full Text] [Related]
15. The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells.
Rowley PT; Keng PC; Kosciolek BA
Leuk Res; 1996 Jun; 20(6):473-80. PubMed ID: 8709619
[TBL] [Abstract][Full Text] [Related]
16. c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers.
Rosti V; Bergamaschi G; Ponchio L; Cazzola M
Leukemia; 1992 Jan; 6(1):1-7. PubMed ID: 1736009
[TBL] [Abstract][Full Text] [Related]
17. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
Skorski T; Kanakaraj P; Nieborowska-Skorska M; Ratajczak MZ; Wen SC; Zon G; Gewirtz AM; Perussia B; Calabretta B
Blood; 1995 Jul; 86(2):726-36. PubMed ID: 7606002
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia.
Diamond J; Goldman JM; Melo JV
Blood; 1995 Apr; 85(8):2171-5. PubMed ID: 7718887
[TBL] [Abstract][Full Text] [Related]
19. Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells.
Käbisch A; Pérènyi L; Seay U; Lohmeyer J; Pralle H
Acta Haematol; 1994; 92(4):190-6. PubMed ID: 7701917
[TBL] [Abstract][Full Text] [Related]
20. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
de Fabritiis P; Skorski T; De Propris MS; Paggi MG; Nieborowska-Skorska M; Lisci A; Buffolino S; Campbell K; Geiser T; Calabretta B
Leukemia; 1997 Jun; 11(6):811-9. PubMed ID: 9177433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
